Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Ticker
$OGN
Sector
Primary listing
NYSE
Employees
10,000
Headquarters
Website
Organon Metrics
BasicAdvanced
$2.5B
13.56
$0.72
0.64
$0.08
0.82%
Price and volume
Market cap
$2.5B
Beta
0.64
52-week high
$13.25
52-week low
$5.69
Average daily volume
6M
Dividend rate
$0.08
Financial strength
Current ratio
1.821
Quick ratio
0.84
Long term debt to equity
1,162.766
Total debt to equity
974.393
Dividend payout ratio (TTM)
47.06%
Interest coverage (TTM)
2.55%
Profitability
EBITDA (TTM)
1,638.333
Gross margin (TTM)
54.09%
Net profit margin (TTM)
3.01%
Operating margin (TTM)
20.67%
Effective tax rate (TTM)
56.00%
Revenue per employee (TTM)
$620,000
Management effectiveness
Return on assets (TTM)
6.22%
Return on equity (TTM)
27.14%
Valuation
Price to earnings (TTM)
13.556
Price to revenue (TTM)
0.407
Price to book
2.8
Price to tangible book (TTM)
-0.56
Price to free cash flow (TTM)
6.595
Free cash flow yield (TTM)
15.16%
Free cash flow per share (TTM)
1.48
Dividend yield (TTM)
0.82%
Forward dividend yield
0.82%
Growth
Revenue change (TTM)
-2.92%
Earnings per share change (TTM)
-78.38%
3-year revenue growth (CAGR)
0.23%
3-year earnings per share growth (CAGR)
-41.47%
3-year dividend per share growth (CAGR)
-32.79%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Organon News
AllArticlesVideos
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
Business Wire·2 days ago
Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Business Wire·3 days ago
Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet
Benzinga·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $2.5B as of April 18, 2026.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 13.56 as of April 18, 2026.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of April 18, 2026, the dividend rate is $0.08 and the yield is 0.82%. Organon has a payout ratio of 47.06% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment date is unconfirmed.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.